Immunotherapy for Infectious Diseases
Immunotherapy for Infectious Diseases Immunotherapy for Infectious Diseases
Index 329 secretory immunoglobulin A, 45, 46 adjuvants and delivery systems, chemokines, 49 cytokines, 49 DNA immunostimulatory sequences, 50 enterotoxin derivatives, CT, 47–49 LT, 47–49 saponin derivatives, 50, 51 inductive sites, 39–41 innate immunity, antimicrobial peptides, 43, 44 chemokines, 44 cytokines, 44 epithelial cell barrier, 43 natural killer cells, 44 lymphocyte homing, bronchus-associated lymphoreticular tissue, 42 discovery, 41 gut-associated lymphoreticular tissue, 42 nasal-associated lymphoreticular tissue, 42 overview, 39, 40 Peyer's patches, 40, 41 tonsils, 41 Mycobacterium, see Leprosy; Tuberculosis N NALT, see Nasal-associated lymphoreticular tissue Nasal-associated lymphoreticular tissue (NALT), see Mucosal immunity Nasopharyngeal carcinoma, see Epstein-Barr virus Natural killer (NK) cell, mucosal immunity, 44 tuberculosis defense, 284 Neisseria, intravenous immunoglobulin, 277 NK cell, see Natural killer cell P Palivizumab, respiratory syncytial virus treatment, 252 Paracoccidioidomycosis, see Fungal infection Passive immunotherapy, discovery, 3 human immunodeficiency virus, antibody combinations, 201, 202 antibody-dependent cellular cytotoxicity, 202, 203, 212 bispecific antibodies, 203 CD4-immunoglobulin fusion compounds, 202 chemokine receptor and coreceptor targeting, 202 clinical trials, monoclonal antibodies, 210, 211 polyclonal antibodies, 211 mechanisms of antibody protective effects, 203, 204 monkey studies, monoclonal antibody protection, 206, 207 postexposure protection with polyclonal antibodies, 206 pre-exposure protection with polyclonal antibodies, 204–206 neutralization epitopes, 200, 212 overview, 75–78 severe combined immunodeficiency mouse studies, antibody-dependent cellular cytotoxicity, 209 complement role, 209 escape mutation, 209 postexposure protection, 209 pre-exposure protection, 207–209 indications, 199 Penicilliosis, see Fungal infection Pentoxifylline, tuberculosis immunotherapy, 291, 292 Peptide-based vaccine, see Vaccine Peyer's patches, see Mucosal immunity Phospholipase A2 (PLA2), secretory enzyme in mucosal innate immunity, 43, 44 PLA2, see Phospholipase A2 Pseudomonas aeruginosa, intravenous immunoglobulin, 277, 278 R Rabies, immunoglobulin therapy, 74 Recombinant protein vaccine, see
330 Index Vaccine Recombinant vector vaccine, see Vaccine Respiratory syncytial virus (RSV), epidemiology, 251 hyperimmune sera, 72 intravenous immunoglobulin therapy, 251, 252 morbidity and mortality, 251 Palivizumab therapy, 252 Rev response element (RRE), human immunodeficiency virus gene therapy, 242, 243 Rheumatoid arthritis, immunoglobulin therapy, 78 RRE, see Rev response element RSV, see Respiratory syncytial virus S Saponin derivatives, mucosal immunity adjuvants, 50, 51 Sepsis, see also specific bacteria, intravenous immunoglobulin therapy, 278 monoclonal antibody therapy, 75 Sporotrichosis, see Fungal infection Staphylococcus aureus, intravenous immunoglobulin, 275, 276 Stat, interferon signal transduction, 122 Streptococcus, intravenous immunoglobulin, 276 Subunit vaccine, see Vaccine T TAR, human immunodeficiency virus gene therapy, 242, 243 T-cell, see also Cytotoxic T-lymphocyte, activation, human immunodeficiency virus therapy targeting, 225, 226, 228, 229 overview, 27–30 antigen, dose response, 29 recognition, 24–26, 130 classes, 29, 30 cytokineproduction, 29, 125–127 response, 27 deletion, 18 helper cell subsets, 30, 125–127, 130 highly active antiretroviral therapy responses, CD4+ cell blood counts, 166–168, 185, 186, 222, 226, 227 CD8+ cells, 170, 171 delayed-type hypersensitivity, 169 proliferative responses, 169, 170 human immunodeficiency virus response, cytotoxic T-lymphocyte, function, 32, 33, 182–185 therapeutic targeting, 229, 230 overview, 29, 31 Leishmania response, 19, 30, 31 lymphocyte proliferation assay, 30, 31 mucosal lymphocyte homing, bronchus-associated lymphoreticular tissue, 42 discovery, 41 gut-associated lymphoreticular tissue, 42 nasal-associated lymphoreticular tissue, 42 recruitment and redistribution, 32, 33 repertoire development, 26, 27 selection, 16, 24, 25 transplantation therapy, cytomegalovirus, 256 Epstein-Barr virus lymphoproliferative disorder, 252–254, 265–267 human immunodeficiency virus, 227, 228 viral defense, 259–261 Thalidomide, tuberculosis immunotherapy, 290, 291 Tonsils, see Mucosal immunity Toxoplasma gondii, dendritic cell response, 101 Transfer factor, fungal infection management, 314 Trypanosoma cruzi, dendritic cell response, 101 Tuberculosis, clinical trials, interferon-α, 289 interferon-γ, 289 interleukin-2, 287–289 interleukin-12, 289, 290 overview, 287 pentoxifylline, 291, 292 thalidomide, 290, 291 vaccination with Mycobacterium vaccae, 292, 293
- Page 290 and 291: Bacterial Infections and Sepsis 279
- Page 292: Bacterial Infections and Sepsis 281
- Page 295 and 296: 284 Wallis and Johnson replication
- Page 297 and 298: 286 Wallis and Johnson Several stud
- Page 299 and 300: 288 Wallis and Johnson monocytes, a
- Page 301 and 302: 290 Wallis and Johnson peripheral b
- Page 303 and 304: 292 Wallis and Johnson (A. Hise and
- Page 305 and 306: 294 Wallis and Johnson infections,
- Page 307 and 308: 296 Wallis and Johnson 37. Boom WH.
- Page 309 and 310: 298 Wallis and Johnson 77. Ellner J
- Page 311 and 312: 300 Wallis and Johnson 113. Raad I,
- Page 313 and 314: 302 Wallis and Johnson 154. Anonymo
- Page 315 and 316: 304 Table 1 Major Fungal Infections
- Page 317 and 318: 306 Casadevall species suggest that
- Page 319 and 320: 308 Casadevall transfusions from G-
- Page 321 and 322: 310 Casadevall Table 3 Augmentation
- Page 323 and 324: 312 Casadevall There has been some
- Page 325 and 326: 314 Casadevall effective in achievi
- Page 327 and 328: 316 Casadevall CONCLUSION AND FUTUR
- Page 329 and 330: 318 Casadevall 16. Boutati EI, Anai
- Page 331 and 332: 320 Casadevall 52. Gallin JI, Malec
- Page 333 and 334: 322 Casadevall 91. Kowanko IC, Ferr
- Page 335 and 336: 324 Index Blastomycosis, see Fungal
- Page 337 and 338: 326 Index C-type retrovirus vectors
- Page 339: 328 Index K Klebsiella, intravenous
- Page 343: Infectious Disease IMMUNOTHERAPY FO
Index 329<br />
secretory immunoglobulin A, 45, 46<br />
adjuvants and delivery systems,<br />
chemokines, 49<br />
cytokines, 49<br />
DNA immunostimulatory<br />
sequences, 50<br />
enterotoxin derivatives,<br />
CT, 47–49<br />
LT, 47–49<br />
saponin derivatives, 50, 51<br />
inductive sites, 39–41<br />
innate immunity,<br />
antimicrobial peptides, 43, 44<br />
chemokines, 44<br />
cytokines, 44<br />
epithelial cell barrier, 43<br />
natural killer cells, 44<br />
lymphocyte homing,<br />
bronchus-associated<br />
lymphoreticular tissue, 42<br />
discovery, 41<br />
gut-associated lymphoreticular<br />
tissue, 42<br />
nasal-associated lymphoreticular<br />
tissue, 42<br />
overview, 39, 40<br />
Peyer's patches, 40, 41<br />
tonsils, 41<br />
Mycobacterium, see Leprosy; Tuberculosis<br />
N<br />
NALT, see Nasal-associated<br />
lymphoreticular tissue<br />
Nasal-associated lymphoreticular tissue<br />
(NALT), see Mucosal immunity<br />
Nasopharyngeal carcinoma, see<br />
Epstein-Barr virus<br />
Natural killer (NK) cell,<br />
mucosal immunity, 44<br />
tuberculosis defense, 284<br />
Neisseria, intravenous immunoglobulin,<br />
277<br />
NK cell, see Natural killer cell<br />
P<br />
Palivizumab, respiratory syncytial virus<br />
treatment, 252<br />
Paracoccidioidomycosis, see Fungal<br />
infection<br />
Passive immunotherapy,<br />
discovery, 3<br />
human immunodeficiency virus,<br />
antibody combinations, 201, 202<br />
antibody-dependent cellular<br />
cytotoxicity, 202, 203, 212<br />
bispecific antibodies, 203<br />
CD4-immunoglobulin fusion<br />
compounds, 202<br />
chemokine receptor and<br />
coreceptor targeting, 202<br />
clinical trials,<br />
monoclonal antibodies, 210, 211<br />
polyclonal antibodies, 211<br />
mechanisms of antibody<br />
protective effects, 203, 204<br />
monkey studies,<br />
monoclonal antibody<br />
protection, 206, 207<br />
postexposure protection with<br />
polyclonal antibodies, 206<br />
pre-exposure protection with<br />
polyclonal antibodies,<br />
204–206<br />
neutralization epitopes,<br />
200, 212<br />
overview, 75–78<br />
severe combined<br />
immunodeficiency mouse<br />
studies,<br />
antibody-dependent cellular<br />
cytotoxicity, 209<br />
complement role, 209<br />
escape mutation, 209<br />
postexposure<br />
protection, 209<br />
pre-exposure protection, 207–209<br />
indications, 199<br />
Penicilliosis, see Fungal infection<br />
Pentoxifylline, tuberculosis<br />
immunotherapy, 291, 292<br />
Peptide-based vaccine, see Vaccine<br />
Peyer's patches, see Mucosal immunity<br />
Phospholipase A2 (PLA2), secretory<br />
enzyme in mucosal innate<br />
immunity, 43, 44<br />
PLA2, see Phospholipase A2<br />
Pseudomonas aeruginosa, intravenous<br />
immunoglobulin, 277, 278<br />
R<br />
Rabies, immunoglobulin therapy, 74<br />
Recombinant protein vaccine, see
Change language